Benitec Biopharma Inc. (BNTC): Price and Financial Metrics
BNTC Price/Volume Stats
| Current price | $6.72 | 52-week high | $9.01 |
| Prev. close | $6.86 | 52-week low | $1.86 |
| Day low | $6.48 | Volume | 66,500 |
| Day high | $7.13 | Avg. volume | 67,561 |
| 50-day MA | $5.01 | Dividend yield | N/A |
| 200-day MA | $3.63 | Market Cap | 17.42M |
BNTC Stock Price Chart Interactive Chart >
Benitec Biopharma Inc. (BNTC) Company Bio
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.
Latest BNTC News From Around the Web
Below are the latest news stories about BENITEC BIOPHARMA INC that investors may wish to consider to help them evaluate BNTC as an investment opportunity.
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular DystrophyAnnouncement marks the initiation of the first clinical trial conducted in human subjects employing Benitec’s “Silence and Replace” DNA-directed RNA interference gene therapy platformHAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, tod |
Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders ConcernsKey Insights Benitec Biopharma will host its Annual General Meeting on 6th of December Total pay for CEO Jerel Banks... |
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare ConferenceHAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec, will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference on Thursday, |
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update19 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment StudyHAYWARD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced financial res |
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational UpdateReceived FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment Study Successful Closing of a $30.9 M Public Offering HAYWARD, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or |
BNTC Price Returns
| 1-mo | 35.48% |
| 3-mo | 118.89% |
| 6-mo | 96.70% |
| 1-year | 98.14% |
| 3-year | -92.93% |
| 5-year | -98.63% |
| YTD | 108.05% |
| 2023 | 11.76% |
| 2022 | -93.51% |
| 2021 | -12.67% |
| 2020 | -60.78% |
| 2019 | -66.00% |
Continue Researching BNTC
Want to see what other sources are saying about Benitec Biopharma LTD's financials and stock price? Try the links below:Benitec Biopharma LTD (BNTC) Stock Price | Nasdaq
Benitec Biopharma LTD (BNTC) Stock Quote, History and News - Yahoo Finance
Benitec Biopharma LTD (BNTC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...